ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec[1] Data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Giuseppe Saglio, Glivec®, imatinib, leukemia, nilotinib, Novartis, Novartis's Tasigna®, Ph+ CML, Phase III studies
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria. The Novartis Foundation for Sustainable Development (NFSD) launches a new strategy to help eliminate leprosy. For over 15 years, the annual symposium of … Read the full press release
The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60 selected students from leading international universities attend to explore science and innovation at Novartis headquarters in Basel, Switzerland Novartis CEO … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Anja von Treskow, Basel, BioCamp, Eric Althoff, healthcare entrepreneur competition, International Biotechnology Leadership Camp, Isabella Zinck, Jill Pozarek, Joseph Jimenez, Novartis, Pierre-Michel Bringer, Prof. Susan Gasser, Rolf M. Zinkernagel M.D., Samir Shah, Stephen Rubino, Thomas Hungerbuehler
Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of … Read the full press release
Posted in European Union, Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Basel, choroidal neovascularization, CNV, Lucentis®, Novartis, RADIANCE, Tim Wright
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged acute heart failure, AHF, Basel, David Epstein, FDA, Novartis, RLX030, serelaxin, US Food and Drug Administration
Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
